Nalls Sherbakoff Group, LLC Calliditas Therapeutics Ab Call Options Transaction History
Nalls Sherbakoff Group, LLC
- $112 Billion
- Q4 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CALT
# of Institutions
6Shares Held
20.3KCall Options Held
0Put Options Held
0-
Crossmark Global Holdings, Inc.16.1KShares$644,6800.01% of portfolio
-
Advisors Preferred, LLC Rockville, MD2.02KShares$80,8800.01% of portfolio
-
Simplex Trading, LLC1.83KShares$73,0400.0% of portfolio
-
Rhumbline Advisers Boston, MA303Shares$12,1200.0% of portfolio
-
Missouri Trust & Investment CO Springfield, MO35Shares$1,4000.0% of portfolio
About Calliditas Therapeutics AB
- Ticker CALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,624,800
- Market Cap $1.06B
- Description
- Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...